These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 21992697)

  • 1. Cellular uptake and intracellular trafficking of antisense and siRNA oligonucleotides.
    Juliano RL; Ming X; Nakagawa O
    Bioconjug Chem; 2012 Feb; 23(2):147-57. PubMed ID: 21992697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular delivery of siRNA and antisense oligonucleotides via receptor-mediated endocytosis.
    Ming X
    Expert Opin Drug Deliv; 2011 Apr; 8(4):435-49. PubMed ID: 21381985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular uptake and intracellular trafficking of oligonucleotides.
    Juliano RL; Carver K
    Adv Drug Deliv Rev; 2015 Jun; 87():35-45. PubMed ID: 25881722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides.
    Juliano R; Alam MR; Dixit V; Kang H
    Nucleic Acids Res; 2008 Jul; 36(12):4158-71. PubMed ID: 18558618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular uptake and intracellular trafficking of oligonucleotides: implications for oligonucleotide pharmacology.
    Juliano RL; Ming X; Carver K; Laing B
    Nucleic Acid Ther; 2014 Apr; 24(2):101-13. PubMed ID: 24383421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Receptors, endocytosis, and trafficking: the biological basis of targeted delivery of antisense and siRNA oligonucleotides.
    Juliano RL; Carver K; Cao C; Ming X
    J Drug Target; 2013 Jan; 21(1):27-43. PubMed ID: 23163768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The delivery of therapeutic oligonucleotides.
    Juliano RL
    Nucleic Acids Res; 2016 Aug; 44(14):6518-48. PubMed ID: 27084936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re-Engineering RNA Molecules into Therapeutic Agents.
    Egli M; Manoharan M
    Acc Chem Res; 2019 Apr; 52(4):1036-1047. PubMed ID: 30912917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracellular Trafficking and Endosomal Release of Oligonucleotides: What We Know and What We Don't.
    Juliano RL
    Nucleic Acid Ther; 2018 Jun; 28(3):166-177. PubMed ID: 29708838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disulfide-Unit Conjugation Enables Ultrafast Cytosolic Internalization of Antisense DNA and siRNA.
    Shu Z; Tanaka I; Ota A; Fushihara D; Abe N; Kawaguchi S; Nakamoto K; Tomoike F; Tada S; Ito Y; Kimura Y; Abe H
    Angew Chem Int Ed Engl; 2019 May; 58(20):6611-6615. PubMed ID: 30884043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted intracellular delivery of antisense oligonucleotides via conjugation with small-molecule ligands.
    Nakagawa O; Ming X; Huang L; Juliano RL
    J Am Chem Soc; 2010 Jul; 132(26):8848-9. PubMed ID: 20550198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The chemistry and biology of oligonucleotide conjugates.
    Juliano RL; Ming X; Nakagawa O
    Acc Chem Res; 2012 Jul; 45(7):1067-76. PubMed ID: 22353142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is there a future for cell-penetrating peptides in oligonucleotide delivery?
    Lee SH; Castagner B; Leroux JC
    Eur J Pharm Biopharm; 2013 Sep; 85(1):5-11. PubMed ID: 23958313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue-Specific Delivery of Oligonucleotides.
    Xia X; Pollock N; Zhou J; Rossi J
    Methods Mol Biol; 2019; 2036():17-50. PubMed ID: 31410789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A status update of modified oligonucleotides for chemotherapeutics applications.
    Sanghvi YS
    Curr Protoc Nucleic Acid Chem; 2011 Sep; Chapter 4():Unit 4.1.1-22. PubMed ID: 21901670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reality check: lipid-oligonucleotide conjugates for therapeutic applications.
    Goodnow RA
    Expert Opin Drug Discov; 2023 Feb; 18(2):129-134. PubMed ID: 36546308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted delivery systems for oligonucleotide therapeutics.
    Yu B; Zhao X; Lee LJ; Lee RJ
    AAPS J; 2009 Mar; 11(1):195-203. PubMed ID: 19296227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid conjugated oligonucleotides: a useful strategy for delivery.
    Raouane M; Desmaële D; Urbinati G; Massaad-Massade L; Couvreur P
    Bioconjug Chem; 2012 Jun; 23(6):1091-104. PubMed ID: 22372953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oligonucleotide delivery: a patent review (2010 - 2013).
    Grijalvo S; Aviñó A; Eritja R
    Expert Opin Ther Pat; 2014 Jul; 24(7):801-19. PubMed ID: 24798406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intra-endosomal trafficking mediated by lysobisphosphatidic acid contributes to intracellular release of phosphorothioate-modified antisense oligonucleotides.
    Wang S; Sun H; Tanowitz M; Liang XH; Crooke ST
    Nucleic Acids Res; 2017 May; 45(9):5309-5322. PubMed ID: 28379543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.